MX2020012475A - Metodo para tratar el trastorno depresivo mayor. - Google Patents

Metodo para tratar el trastorno depresivo mayor.

Info

Publication number
MX2020012475A
MX2020012475A MX2020012475A MX2020012475A MX2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A
Authority
MX
Mexico
Prior art keywords
depressive disorder
major depressive
treating major
treating
disorder
Prior art date
Application number
MX2020012475A
Other languages
English (en)
Inventor
Elena Kagan
Petra Luise Goelzer
Original Assignee
Clexio Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clexio Biosciences Ltd filed Critical Clexio Biosciences Ltd
Publication of MX2020012475A publication Critical patent/MX2020012475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para la administración segura y eficaz de esketamina.
MX2020012475A 2018-06-27 2019-06-27 Metodo para tratar el trastorno depresivo mayor. MX2020012475A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690419P 2018-06-27 2018-06-27
US201862698323P 2018-07-16 2018-07-16
US201862741564P 2018-10-05 2018-10-05
US201862769264P 2018-11-19 2018-11-19
PCT/IB2019/055453 WO2020003195A1 (en) 2018-06-27 2019-06-27 Method of treating major depressive disorder

Publications (1)

Publication Number Publication Date
MX2020012475A true MX2020012475A (es) 2021-04-28

Family

ID=67909427

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012475A MX2020012475A (es) 2018-06-27 2019-06-27 Metodo para tratar el trastorno depresivo mayor.

Country Status (10)

Country Link
US (1) US12036189B2 (es)
EP (1) EP3813807A1 (es)
JP (2) JP2021529732A (es)
KR (1) KR20210028159A (es)
CN (1) CN112188889A (es)
BR (1) BR112020023882A2 (es)
CA (1) CA3103440A1 (es)
IL (1) IL278759B1 (es)
MX (1) MX2020012475A (es)
WO (1) WO2020003195A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
US20230063459A1 (en) 2019-12-30 2023-03-02 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8785500B2 (en) 2006-03-22 2014-07-22 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
NZ589764A (en) 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
US9468611B2 (en) 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
KR102424765B1 (ko) 2013-04-12 2022-07-22 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
JP2016531913A (ja) * 2013-08-26 2016-10-13 アモーサ セラピューティックス， インコーポレイテッドＡｍｏｒｓａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 神経抑制性ケタミンの単層による経口投与
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
EA032013B1 (ru) 2013-10-31 2019-03-29 Сайма Лэбс Инк. Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
ES2935800T3 (es) 2014-04-17 2023-03-10 Ketabon Gmbh Forma de dosificación oral de ketamina
CN107208133A (zh) * 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
RS65411B1 (sr) 2014-11-04 2024-05-31 Acadia Pharm Inc Jedinjenja neuroatenuirajućeg norketamina i metodi
WO2016094358A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
US11110070B2 (en) 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
IL315066A (en) 2016-10-27 2024-10-01 Univ Chiba Nat Univ Corp Pharmaceutical applications of (S)-norketamine and its salts
US20210113493A1 (en) 2016-11-30 2021-04-22 Philip E. Wolfson Ketamine for the treatment of menstrually related symptoms
EP3641742A2 (en) 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
CA3077645A1 (en) 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. A solid extended-release pharmaceutical formulations comprising ketamine or norketamine
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
AU2020324432A1 (en) 2019-08-05 2021-10-07 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
US20230063459A1 (en) 2019-12-30 2023-03-02 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Also Published As

Publication number Publication date
CA3103440A1 (en) 2020-01-02
IL278759B1 (en) 2024-08-01
CN112188889A (zh) 2021-01-05
US12036189B2 (en) 2024-07-16
AU2019293515A1 (en) 2020-12-03
BR112020023882A2 (pt) 2021-02-09
KR20210028159A (ko) 2021-03-11
JP2024041855A (ja) 2024-03-27
WO2020003195A1 (en) 2020-01-02
US20200000748A1 (en) 2020-01-02
EP3813807A1 (en) 2021-05-05
JP2021529732A (ja) 2021-11-04
IL278759A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
MX2020012475A (es) Metodo para tratar el trastorno depresivo mayor.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
MX2021003903A (es) Terapia combinada para el melanoma.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2017009246A (es) Farmaco de combinacion.
MX2020006297A (es) Variantes de cd19.
PH12018550186A1 (en) Pharmaceutical combinations for treating cancer
ZA201807438B (en) Methods of treating ocular conditions
IL280845A (en) Asketamine dose adjustment for the treatment of clinical depression
MX2019014024A (es) Tratamiento de los trastornos depresivos.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2021006326A (es) Inhibidores de pcna.
AU2018337076A1 (en) Method of treatment
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
PH12017500275A1 (en) Methods of treating depression using nmda modulators